Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
Sildenafil To Prevent Clot (SToPClot)

complications of stroke, the hematologic mechanisms behind these devastating adverse events remain uncertain. Recently, it has been recognized that CF pump induced hemolysis precedes and is associated with

sickle cell anemia
heart failure
clot
thrombosis
platelet aggregation
  • 0 views
  • 03 Feb, 2022
  • 1 location
Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury (ICAROX2)

renal outcome (biomarkers and renal oxygenation/renal blood flow), as well as markers of inflammation and hemolysis. Additionally, urine oxygen tension will be measured during CPB and the early

  • 0 views
  • 11 May, 2022
  • 1 location
Home Hemodialysis Assisted by a Nurse for Arterio-venous Fistula Cannulation (DIADIDEAL)

Home HD (HHD) is associated with better outcome in end-stage renal disease patients compared to in-center HD, in particular in terms of quality of life. However fear of AVF cannulation is a known barrier for patient's choice and adoption of a HHD program. Providing nurse assistance for the cannulation can …

renal disease
  • 9 views
  • 04 Feb, 2022
  • 1 location
Effects of Nitric Oxide on the Endothelium During Hemolysis.

the effects of Nitric Oxide on vascular responsiveness and on endothelial function during hemolysis in patients with pre-operative endothelial dysfunction undergoing cardiac surgery requiring

endothelial dysfunction
cardiac surgery
reactive hyperemia
nitric oxide
  • 6 views
  • 01 Feb, 2022
  • 1 location
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS 2)

The primary objective of the study is: To evaluate the effect of pozelimab and cemdisiran combination therapy on hemolysis, as assessed by lactate dehydrogenase (LDH), after 36 weeks of

ravulizumab
flow cytometry
fatigue
hemolysis
eculizumab
  • 0 views
  • 25 Mar, 2022
Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST) (SAST)

Aspirin was reported to induce hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency on some occasions, while still widely uesd for stroke prevention. The SAST trial is

aspirin
ischemic stroke
clopidogrel
  • 0 views
  • 26 Feb, 2022
Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury (DEFEAT-AKI)

models. Patients undergoing cardiac surgery may be particularly susceptible to iron-mediated kidney injury due to the profound hemolysis that often occurs from cardiopulmonary bypass. The investigators

cardiopulmonary bypass
  • 0 views
  • 24 Mar, 2022
  • 3 locations
Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

> The secondary objectives of the study are: To evaluate the effect of the combination treatment on the following parameters of intravascular hemolysis: lactate dehydrogenase (LDH) control

flow cytometry
fatigue
hemolysis
eculizumab
lactate dehydrogenase
  • 4 views
  • 29 Apr, 2022
  • 1 location
Acute Kidney Injury After Cardiac Surgery

comparing PrimECC with crystalloid priming fluid, patients in the PrimECC group experienced less hemolysis, less tubular cell injury and beneficial effect on the fluid balance. This study will investigate

crystalloid solutions
heart surgery
renal injury
hemolysis
extracorporeal circulation
  • 0 views
  • 11 May, 2022
  • 1 location
Ravulizumab-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy (ACCESS-1)

The primary objective of the study is: To evaluate the effect on hemolysis and red blood cells (RBC) transfusions over a 24-week treatment period of pozelimab and cemdisiran combination

ravulizumab
complement inhibitor
flow cytometry
fatigue
hemolysis
  • 0 views
  • 26 May, 2022
  • 1 location